FDA Accepts Application for Mezigdomide in Multiple Myeloma Treatment

The U.S. FDA has accepted a New Drug Application for mezigdomide, proposed for use in combination therapy for patients with relapsed or refractory multiple myeloma. A decision from the regulatory agency is expected by May 13, 2027. This application is supported by positive results from the phase 3 SUCCESSOR-2 trial, which showed improved progression-free survival, offering potential new options for patients.